Strontium-89 was first synthesized in 1937 by D. W. Stewart et al. at the University of Michigan; it was synthesized via irradiation of stable strontium (88Sr) with deuterons.[3] Biological properties and applications of strontium-89 were studied for the first time by Belgian scientist Charles Pecher.[4][5] Pecher filed a patent in May 1941 for the synthesis of strontium-89 and yttrium-86 using cyclotrons, and described the therapeutic use of strontium.[6]
Physiological effects and medical use
Metastron, a preparation of strontium-89 chloride made by GE Healthcare and used for purposes such as prostate cancer treatment.[7]
Strontium belongs to the same periodic family as calcium (alkaline earth metals), and is metabolised in a similar fashion, preferentially targeting metabolically active regions of the bone. 89Sr is an artificial radioisotope used in the treatment of osseous (bony) metastases of bone cancer.[8][9]
In circumstances where cancer patients have widespread and painful bony metastases, the administration of 89Sr results in the delivery of beta particles directly to the area of bony problem, where calcium turnover is greatest.[10] Consequently, intravenous or intracavity administration of 89Sr may be helpful in the palliation of painful bony metastases, as it allows radiation to be targeted at metastatic lesions, inducing apoptosis of cells, membrane and protein damage. Subsequently, bone pain resulting from cytokine release at the site of lesions, bone-associated nerve compression and stretching of the periosteum may be reduced. Treatment with 89Sr has been particularly effective in patients with hormonally-resistant prostate cancer, often leading to a decreased requirement for opioid analgesics, an increase in time until further radiation is needed, and a decrease in tumour markers.
^Delacroix, D.; Guerre, J. P.; Leblanc, P.; Hickman, C. (1 January 2002). "Radionuclide and Radiation Protection Data Handbook 2002". Radiation Protection Dosimetry. 98 (1): 79. doi:10.1093/oxfordjournals.rpd.a006705. PMID 11916063.
^Audi, Georges; Wapstra, Aaldert Hendrik; Thibault, Catherne; Blachot, Jean; Bersillon, Olivier (2003). (PDF). Nuclear Physics A. 729 (1): 3–128. Bibcode:2003NuPhA.729....3A. CiteSeerX10.1.1.692.8504. doi:10.1016/j.nuclphysa.2003.11.001. Archived from the original (PDF) on 2011-07-20.
^Parker, A. M.; Thoennessen, M. (2012). "Discovery of rubidium, strontium, molybdenum, and rhodium isotopes". Atomic Data and Nuclear Data Tables. 98 (4): 812–831. arXiv:1102.2388. doi:10.1016/j.adt.2012.06.001.
^Pecher, Charles (1941). "Biological Investigations with Radioactive Calcium and Strontium". Proceedings of the Society for Experimental Biology and Medicine. 46 (1): 86–91. doi:10.3181/00379727-46-11899. ISSN 0037-9727. S2CID 88173163.
^Pecher, Charles (1942). Biological investigations with radioactive calcium and strontium; preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Vol. 2. University of California Publications in Pharmacology. pp. 117–150. OCLC 7837554.
^US 2302470, Pecher, Charles, "Material and method for radiography", published 1941-05-14
^Halperin, Edward C.; Perez, Carlos A.; Brady, Luther W. (2008). Perez and Brady's principles and practice of radiation oncology. Lippincott Williams & Wilkins. pp. 1997–. ISBN978-0-7817-6369-1. Retrieved 19 July 2011.
^Bauman, Glenn; Charette, Manya; Reid, Robert; Sathya, Jinka (2005). "Radiopharmaceuticals for the palliation of painful bone metastases—a systematic review". Radiotherapy and Oncology. 75 (3): 258.E1–258.E13. doi:10.1016/j.radonc.2005.03.003. ISSN 0167-8140. PMID 16299924.
^Mertens, W. C.; Filipczak, L. A.; Ben-Josef, E.; Davis, L. P.; Porter, A. T. (1998). "Systemic bone-seeking radionuclides for palliation of painful osseous metastases: current concepts". CA: A Cancer Journal for Clinicians. 48 (6): 361–374. doi:10.3322/canjclin.48.6.361. ISSN 0007-9235. PMID 9838899.
March 08, 2023
strontium, radioactive, isotope, strontium, produced, nuclear, fission, with, half, life, days, undergoes, decay, into, yttrium, application, medicine, 89srgeneralsymbol89srnamesstrontium, 89sr, 89protons, 38neutrons, 51nuclide, datanatural, abundancesynhalf, . Strontium 89 89 Sr is a radioactive isotope of strontium produced by nuclear fission with a half life of 50 57 days It undergoes b decay into yttrium 89 Strontium 89 has an application in medicine 2 Strontium 89 89SrGeneralSymbol89SrNamesstrontium 89 89Sr Sr 89Protons Z 38Neutrons N 51Nuclide dataNatural abundancesynHalf life t1 2 50 57 dDecay products89YDecay modesDecay modeDecay energy MeV Beta decay1 492 1 Isotopes of strontium Complete table of nuclides Contents 1 History 2 Physiological effects and medical use 3 See also 4 ReferencesHistory EditStrontium 89 was first synthesized in 1937 by D W Stewart et al at the University of Michigan it was synthesized via irradiation of stable strontium 88Sr with deuterons 3 Biological properties and applications of strontium 89 were studied for the first time by Belgian scientist Charles Pecher 4 5 Pecher filed a patent in May 1941 for the synthesis of strontium 89 and yttrium 86 using cyclotrons and described the therapeutic use of strontium 6 Physiological effects and medical use Edit Metastron a preparation of strontium 89 chloride made by GE Healthcare and used for purposes such as prostate cancer treatment 7 Strontium belongs to the same periodic family as calcium alkaline earth metals and is metabolised in a similar fashion preferentially targeting metabolically active regions of the bone 89Sr is an artificial radioisotope used in the treatment of osseous bony metastases of bone cancer 8 9 In circumstances where cancer patients have widespread and painful bony metastases the administration of 89Sr results in the delivery of beta particles directly to the area of bony problem where calcium turnover is greatest 10 Consequently intravenous or intracavity administration of 89Sr may be helpful in the palliation of painful bony metastases as it allows radiation to be targeted at metastatic lesions inducing apoptosis of cells membrane and protein damage Subsequently bone pain resulting from cytokine release at the site of lesions bone associated nerve compression and stretching of the periosteum may be reduced Treatment with 89Sr has been particularly effective in patients with hormonally resistant prostate cancer often leading to a decreased requirement for opioid analgesics an increase in time until further radiation is needed and a decrease in tumour markers See also EditIsotopes of strontium Alpharadin radium 223 with similar clinical useReferences Edit Delacroix D Guerre J P Leblanc P Hickman C 1 January 2002 Radionuclide and Radiation Protection Data Handbook 2002 Radiation Protection Dosimetry 98 1 79 doi 10 1093 oxfordjournals rpd a006705 PMID 11916063 Audi Georges Wapstra Aaldert Hendrik Thibault Catherne Blachot Jean Bersillon Olivier 2003 The NUBASE evaluation of nuclear and decay properties PDF Nuclear Physics A 729 1 3 128 Bibcode 2003NuPhA 729 3A CiteSeerX 10 1 1 692 8504 doi 10 1016 j nuclphysa 2003 11 001 Archived from the original PDF on 2011 07 20 Parker A M Thoennessen M 2012 Discovery of rubidium strontium molybdenum and rhodium isotopes Atomic Data and Nuclear Data Tables 98 4 812 831 arXiv 1102 2388 doi 10 1016 j adt 2012 06 001 Pecher Charles 1941 Biological Investigations with Radioactive Calcium and Strontium Proceedings of the Society for Experimental Biology and Medicine 46 1 86 91 doi 10 3181 00379727 46 11899 ISSN 0037 9727 S2CID 88173163 Pecher Charles 1942 Biological investigations with radioactive calcium and strontium preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer Vol 2 University of California Publications in Pharmacology pp 117 150 OCLC 7837554 US 2302470 Pecher Charles Material and method for radiography published 1941 05 14 Strontium 89 Metastron treatment QEH Birmingham NHS Retrieved 23 November 2015 Halperin Edward C Perez Carlos A Brady Luther W 2008 Perez and Brady s principles and practice of radiation oncology Lippincott Williams amp Wilkins pp 1997 ISBN 978 0 7817 6369 1 Retrieved 19 July 2011 Bauman Glenn Charette Manya Reid Robert Sathya Jinka 2005 Radiopharmaceuticals for the palliation of painful bone metastases a systematic review Radiotherapy and Oncology 75 3 258 E1 258 E13 doi 10 1016 j radonc 2005 03 003 ISSN 0167 8140 PMID 16299924 Mertens W C Filipczak L A Ben Josef E Davis L P Porter A T 1998 Systemic bone seeking radionuclides for palliation of painful osseous metastases current concepts CA A Cancer Journal for Clinicians 48 6 361 374 doi 10 3322 canjclin 48 6 361 ISSN 0007 9235 PMID 9838899 Retrieved from https en wikipedia org w index php title Strontium 89 amp oldid 1138049115, wikipedia, wiki, book, books, library,
